远程医疗公司Hims & Hers Health Inc.（股票代码：HIMS）周二盘前股价大跌15.01%，主要原因是该公司公布的第二季度财报未能达到市场预期，同时公司还面临着潜在的法律风险。
根据公司发布的财报，Hims & Hers第二季度营收为5.448亿美元，同比增长72.6%，但低于分析师预期的5.52亿美元。尽管公司报告的每股收益为17美分，高于预期的15美分，但营收的失利仍然引发了投资者的担忧。值得注意的是，公司的GLP-1减肥药业务收入从第一季度的2.3亿美元下降到了1.9亿美元，这一下滑趋势令市场感到不安。
除了财务表现不佳外，Hims & Hers还面临着更为严峻的挑战。公司正在面临一项证券集体诉讼，被指控推广和销售非法版本的减肥药Wegovy。这些药品据称由不受监管的外国供应商制造，不仅涉嫌违法，还可能危及患者安全。更糟糕的是，原本与Hims & Hers建立合作关系的诺和诺德公司已宣布终止双方的合作。这一系列负面消息严重打击了投资者信心，可能会对公司的声誉和未来业务发展造成重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.